We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+17%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$9.33B
AUM Growth
+$1.78B
Cap. Flow
+$552M
Cap. Flow %
5.91%
Top 10 Hldgs %
20.52%
Holding
814
New
78
Increased
378
Reduced
271
Closed
33

Top Buys

Rank Stock Value
1
MSFT icon
Microsoft
MSFT
+$50.3M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$39.4M
3
INTC icon
Intel
INTC
+$29.2M
4
QCOM icon
Qualcomm
QCOM
+$27.6M
5
DHR icon
Danaher
DHR
+$26M

Top Sells

Rank Stock Value
1
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$49.9M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$41.6M
3
ARQL
Arqule Inc
ARQL
+$26.5M
4
ARWR icon
Arrowhead Research
ARWR
+$24.9M
5
MRK icon
Merck
MRK
+$15.4M

Sector Composition

Rank Sector Weight
1 Healthcare 30.73%
2 Technology 19.55%
3 Financials 10.18%
4 Consumer Discretionary 9.32%
5 Communication Services 8.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MEOH icon
776
Methanex
MEOH
$4.32B
– –
-43,995
Closed -$1.56M
NTLA icon
777
Intellia Therapeutics
NTLA
$1.5B
– –
-120,000
Closed -$1.6M
RL icon
778
Ralph Lauren
RL
$22.2B
– –
-2,644
Closed -$252K
SEE
779
DELISTED
Sealed Air
SEE
– –
-5,828
Closed -$242K
SKM icon
780
SK Telecom
SKM
$13.7B
– –
-10,789
Closed -$395K
SPB icon
781
Spectrum Brands
SPB
$2.04B
– –
-5,558
Closed -$293K
W icon
782
Wayfair
W
$11.1B
– –
-3,761
Closed -$422K
SYRS
783
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-16,900
Closed -$1.75M
CBAY
784
DELISTED
Cymabay Therapeutics
CBAY
– –
-338,000
Closed -$1.73M
KDNY
785
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
– –
-47,800
Closed -$253K
PHAS
786
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
– –
-105,423
Closed -$440K
KL
787
DELISTED
Kirkland Lake Gold Ltd Ordinary
KL
– –
-6,189
Closed -$277K
CIT
788
DELISTED
CIT Group Inc.
CIT
– –
-22,361
Closed -$1.01M
LJPC
789
DELISTED
La Jolla Pharmaceutical Company
LJPC
– –
-326,300
Closed -$2.87M
28 29 30 31
32

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q4 2019 Portfolio in Review

As of Q4 2019, Candriam SCA held 814 positions worth $9.33B, up 24% from $7.55B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Candriam SCA deployed $552M of net new capital in Q4 2019, opening 78 new positions and adding to 378 existing holdings. Its largest new stake was Vipshop: 2,005,000 shares worth $28.4M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Ra Pharmaceuticals, Inc. Common Stock, an estimated $49.9M trimmed.

  • Candriam SCA's largest Q4 2019 buy was Vipshop: 2,005,000 shares worth $28.4M.
  • Candriam SCA added most to Microsoft in Q4 2019, an estimated $50.3M increase.
  • Candriam SCA's biggest Q4 2019 reduction was Ra Pharmaceuticals, Inc. Common Stock, cutting an estimated $49.9M.
  • Candriam SCA fully exited Hilton Worldwide in Q4 2019, selling an estimated $11.8M.
  • Candriam SCA's ten largest holdings make up 21% of its $9.33B portfolio in Q4 2019.
  • Candriam SCA opened 78 new positions and closed 33 in Q4 2019.
  • Candriam SCA's portfolio value rose 24% quarter-over-quarter to $9.33B.

Based on Candriam SCA's 13F filing for Q4 2019, filed 21 Jan 2020.